United States Biotechnology & Medical Research

CinCor Pharma Inc (CINC)

Track

Ticker: CINC Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for CinCor Pharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 28 Nov 2022
Value US$3,861,740.61 | Price 108.87 | Shares 87,041 (+12.5%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-02-27 2022-11-28 S Sale
2.9
HEALY JAMES
Non-Executive Director Large shareholder
87,041 +12.5%
108.87
US$3,861,741 		87,041 +12.5% 108.87 US$3,861,741
2022-08-17 2022-08-15 B Purchase
2.6
5AM Partners VI, LLC
Large shareholder
90,660 +27.6%
116.04
US$1,393,225 		90,660 +27.6% 116.04 US$1,393,225
2022-08-17 2022-08-15 B Purchase
2.6
5AM Partners VI, LLC
Large shareholder
29,604 +3.0%
45.23
US$1,121,201 		29,604 +3.0% 45.23 US$1,121,201
2022-08-17 2022-08-15 B Purchase
1.8
Sofinnova Partners SAS
Large shareholder
133,333 +3.3%
30.00
US$3,999,990 		133,333 +3.3% 30.00 US$3,999,990
2022-08-15 2022-08-11 B Purchase
3.4
GENERAL ATLANTIC GENPAR (BERMUDA), L.P.
Large shareholder
83,000 +2.0%
30.00
US$2,490,000 		83,000 +2.0% 30.00 US$2,490,000
2022-08-15 2022-08-11 B Purchase
2.5
Sofinnova Venture Partners X, L.P.
Large shareholder
500,000 +9.0%
30.00
US$15,000,000 		500,000 +9.0% 30.00 US$15,000,000
2022-08-15 2022-08-11 B Purchase
3.1
GENERAL ATLANTIC, L.P.
Large shareholder
83,000 +2.0%
30.00
US$2,490,000 		83,000 +2.0% 30.00 US$2,490,000
2022-08-15 2022-08-11 B Purchase
2.9
HEALY JAMES
Non-Executive Director Large shareholder
6,000 +inf%
30.00
US$180,000 		6,000 +inf% 30.00 US$180,000
2022-08-15 2022-08-11 B Purchase
2.9
HEALY JAMES
Non-Executive Director Large shareholder
500,000 +9.0%
30.00
US$15,000,000 		500,000 +9.0% 30.00 US$15,000,000
2023-02-27 2022-06-10 S Sale
3.3
Freeman Mason

Chief Medical Officer

Officer
6 -0.2%
15.21
US$91 		6 -0.2% 15.21 US$91
2022-01-13 2022-01-11 B Purchase
3.8
Coelho Mary Theresa

EVP CFO & Chief BD Officer

Officer
100 +inf%
16.00
US$1,600 		100 +inf% 16.00 US$1,600
2022-01-13 2022-01-11 B Purchase
2.5
Sofinnova Venture Partners X, L.P.
Large shareholder
325,000 +6.2%
16.00
US$5,200,000 		325,000 +6.2% 16.00 US$5,200,000
2022-01-13 2022-01-11 B Purchase
2.9
HEALY JAMES
Non-Executive Director Large shareholder
325,000 +6.2%
16.00
US$5,200,000 		325,000 +6.2% 16.00 US$5,200,000
2022-01-13 2022-01-11 B Purchase
1.8
Sofinnova Partners SAS
Large shareholder
220,000 +5.7%
16.00
US$3,520,000 		220,000 +5.7% 16.00 US$3,520,000
2022-01-13 2022-01-11 B Purchase
2.6
5AM Partners VI, LLC
Large shareholder
312,500 +170.0%
16.00
US$5,000,000 		312,500 +170.0% 16.00 US$5,000,000
2022-01-13 2022-01-11 B Purchase
2.6
5AM Partners VI, LLC
Large shareholder
157,500 +4.3%
16.00
US$2,520,000 		157,500 +4.3% 16.00 US$2,520,000
2022-01-13 2022-01-11 B Purchase
3.4
GENERAL ATLANTIC GENPAR (BERMUDA), L.P.
Large shareholder
1,700,000 +70.1%
16.00
US$27,200,000 		1,700,000 +70.1% 16.00 US$27,200,000
2022-01-13 2022-01-11 B Purchase
3.3
de Garidel Marc

Chief Executive Officer

Executive Director
12,500 +inf%
16.00
US$200,000 		12,500 +inf% 16.00 US$200,000
2022-01-13 2022-01-11 B Purchase
3.3
Pearce Catherine

Chief Operating Officer

Officer
1,500 +inf%
16.00
US$24,000 		1,500 +inf% 16.00 US$24,000
2022-01-13 2022-01-11 B Purchase
3.3
Pearce Catherine

Chief Operating Officer

Officer
750 +0.6%
16.00
US$12,000 		750 +0.6% 16.00 US$12,000
2022-01-13 2022-01-11 B Purchase
3.3
Freeman Mason

EVP Clinical Development

Officer
100 +inf%
16.00
US$1,600 		100 +inf% 16.00 US$1,600
2022-01-13 2022-01-11 B Purchase
3.3
Freeman Mason

EVP Clinical Development

Officer
2,500 +inf%
16.00
US$40,000 		2,500 +inf% 16.00 US$40,000
2022-01-13 2022-01-11 B Purchase
3.1
GENERAL ATLANTIC, L.P.
Large shareholder
1,700,000 +70.1%
16.00
US$27,200,000 		1,700,000 +70.1% 16.00 US$27,200,000
Explore more

More insider trading research around CinCor Pharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America